Aortic Valve Neocuspidization using glutaraldehyde-treated autologous
pericardium: A literature review
Jeremy Chan1,
Ayan Basu2, Gabriela Discenza3, Jack
Bartlett4, Ka Siu Fan5, Shwe
Oo6
1: MB BCh BAO, PgDip (ClinEd), Bristol Medical School, University of
Bristol, Bristol, United Kingdom
2: MSc, BSc, MBBS, St George’s University of London, London, United
Kingdom
3: St George’s University of London, London, United Kingdom
4: MSc, BSc, Swansea University Medical School, Swansea, United Kingdom
5: BSc, St. George’s University of London, London, United Kingdom
6: MRCS, PgCert (ClinEd), Department of Cardiothoracic Surgery, Bristol
Royal Infirmary, Bristol, United Kingdom
Corresponding author
Dr Jeremy Chan
MB BCh BAO, PgDip (ClinEd)
Bristol Medical School
University of Bristol, Bristol, United Kingdom
Email:jeremychan@doctors.org.uk
Keywords: Aortic Valve Neocuspidization, Ozaki technique, Literature
review
Word Count:
Funding: (None)
Disclosure: Nil
Acknowledgement: Nil
Presentation: Nil
Abstract
Background: Aortic Valve Neocuspidization using glutaraldehyde-treated
autologous pericardium was first performed by Ozaki et al. in
2007. This technique has become an alternative to tissue and mechanical
valve as long-term anticoagulation is not required and shows promising
midterm results and durability.
Method: A comprehensive search was performed on the major database using
search terms “Ozaki technique” AND “Aortic Valve Neocuspidization”
AND “AV Neocuspidization” AND “Autologous pericardium” AND
“glutaraldehyde-treated autologous pericardium”. Articles up to
1st of August 2020 were included in this study.
Results: A total of 9 studies with a total of 1342 patients were
included. The mean age was 67.36 and 54.23% were male. 66.32% and
23.92% of patients had aortic stenosis and aortic regurgitation,
respectively. 66% of patients had a native tricuspid aortic valve and
31.37 % patients’ native aortic valve was bicuspid. Three studies
reported their experience performing Aortic Valve Neocuspidization via
mini sternotomy.
Conclusion: Aortic Valve Neocuspidization is an alternative to
biological and mechanical prostheses for surgical aortic valve
replacement. The short and mid-term outcome are comparable without the
need for long term oral anticoagulation. Long term follow-up data is
required for this novel approach to be widely adopted.